Shots:
- The US FDA has approved Susvimo (port delivery platform with Lucentis) to treat DME
Approval was based on P-III (Pagoda) study assessing Susvimo (100 mg/mL, refilled in Q6M) vs Lucentis (0.5mg, intravitreal, Q1M) in DME pts (n=634), where subjects in - Susvimo arm received 4 loading doses of Lucentis till 16wks. prior to implantation
Study demonstrated sustained vision improvements with 9.6 vs 9.4 letters on eye chart, showing non-inferiority of Susvimo
Ref: Roche | Image: Roche
Related News:- Roche Reports Topline Data from P-III (INAVO120) Trial of Itovebi (Inavolisib) to Treat HR-Positive Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
